Literature DB >> 22549498

Diminished mycophenolic acid exposure caused by omeprazole may be clinically relevant in the first week posttransplantation.

Elias David-Neto1, Kelly M Takaki, Fabiana Agena, Paschoalina Romano, Nairo M Sumita, Maria E Mendes, Leticia Aparecida Lopes Neri, William C Nahas.   

Abstract

BACKGROUND: Some studies have reported a decreased absorption of mycophenolic acid (MPA) from mycophenolate mofetil (MMF) in renal transplanted (RTx) patients under proton-pump inhibitors (PPIs). There is still a lack of information regarding (1) whether this effect occurs when MMF is administered with either tacrolimus or cyclosporine A [calcineurin inhibitors (CNIs)], (2) whether the effect has the same amplitude during the first year after RTx, and finally (3) whether this decrease in exposure is clinically relevant.
METHODS: We retrospectively analyzed the omeprazole effect in 348 12-hour pharmacokinetic samplings [area under the curve (AUC)(0-12h)] performed on days 7, 14, 30, 60, 180, and 360 after RTx in 77 patients who participated in previous trials.
RESULTS: For all periods, the groups with and without PPI did not differ in all variables. By mixed-model analysis of variance, PPI reduced the MPA AUC(0-12h) (P < 0.0008) in the patients under both CNIs mainly due to decreased absorption (P = 0.049). In the tacrolimus group, a lower exposure seemed also due to a decreased MPA reabsorption at 10-12 hours. The PPI effect remains throughout the first year but was clinically more important on day 7. By Cox analysis, the use of PPI was associated with a 25% less chance of being adequately exposed to MPA (95% confidence interval 0.58-0.99, P = 0.04). Similarly, the number of patients underexposed to MPA (AUC < 30 ng·h/mL) was higher at most periods in the PPI group but again not statistically significant.
CONCLUSIONS: These data indicate that PPI decreases the MPA exposure when associated with both CNIs but particularly in the first week after RTx. In this period, the MMF dose should be increased. This effect lasts throughout the first year but does not seem to be clinically relevant after the first week.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22549498     DOI: 10.1097/FTD.0b013e31824d6e8e

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  5 in total

1.  Prevalence and nature of potential drug-drug interactions among kidney transplant patients in a German intensive care unit.

Authors:  Julia Amkreutz; Alexander Koch; Lukas Buendgens; Anja Muehlfeld; Christian Trautwein; Albrecht Eisert
Journal:  Int J Clin Pharm       Date:  2017-08-19

Review 2.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.

Authors:  Azrin N Abd Rahman; Susan E Tett; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447

3.  Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management.

Authors:  Wei Li; Su Zeng; Lu-Shan Yu; Quan Zhou
Journal:  Ther Clin Risk Manag       Date:  2013-05-27       Impact factor: 2.423

4.  Different Routes of Proton Pumps Inhibitors Co-Administration have Significant Impact on Mycophenolate Acid (MPA) Serum Levels in Heart Transplant Recipients.

Authors:  Tomasz Urbanowicz; Ewa Straburzyńska-Migaj; Veronica Casadei; Michał Bociański; Marek Jemielity
Journal:  Ann Transplant       Date:  2020-01-24       Impact factor: 1.530

5.  The impact of omeprazole on mycophenolate pharmacokinetics in kidney transplant recipients.

Authors:  Mohamed S AbdElhalim; Ahmed S Kenawy; Heba H El Demellawy; Amany A Azouz; Sarah S Alghanem; Torki Al-Otaibi; Osama Gheith; Mohamed Abd ElMonem; Mohammed K Afifi; Raghda R S Hussein
Journal:  Kidney Res Clin Pract       Date:  2020-12-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.